Amerise Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	0.16	0.06	-1.46	-1.19	5.49
Other Operating Activities	-	-	-0	-	-
Change in Accounts Receivable	-	-	-	62.17	-62.17
Change in Accounts Payable	-	-	-	-62.66	57.85
Change in Other Net Operating Assets	-10.73	30.65	-0.23	0.36	-0.56
Operating Cash Flow	-10.57	30.71	-1.69	-1.32	0.61
Investment in Securities	-13.89	-1.16	23.01	1.26	-16.51
Investing Cash Flow	16.26	-30.7	2.67	1.26	-1.51
Short-Term Debt Issued	-	-	-	0.07	0.83
Total Debt Issued	-	-	-	0.07	0.83
Short-Term Debt Repaid	-	-	-0.9	-	-
Total Debt Repaid	-	-	-0.9	-	-
Net Debt Issued (Repaid)	-	-	-0.9	0.07	0.83
Financing Cash Flow	-	-	-0.9	0.07	0.83
Miscellaneous Cash Flow Adjustments	-	-	-	-0	0
Net Cash Flow	5.7	0.01	0.08	0.01	-0.06
Cash Income Tax Paid	-	0.02	-	-	-
Levered Free Cash Flow	-10.6	30.7	-1.14	-1.17	-1.44
Unlevered Free Cash Flow	-10.6	30.7	-1.14	-1.17	-1.44
Change in Working Capital	-10.73	30.65	-0.23	-0.13	-4.88

Source: S&P Global Market Intelligence. Standard template. Financial Sources.